Screener
Corcept Therapeutics CORT Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Commitments and contingencies (Note 4) | ||
| Stockholders’ equity: | ||
| Preferred stock | — | — |
| Common stock | 142 | 140 |
| Treasury stock | (998,013) | (966,586) |
| Additional paid-in capital | 1,048,598 | 968,600 |
| Accumulated other comprehensive income | 436 | 2,264 |
| Retained earnings | 654,613 | 643,387 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's common stock?
- Corcept Therapeutics (CORT) reported common stock of $142K in Q2 2026.
- How has Corcept Therapeutics's common stock changed year-over-year?
- Corcept Therapeutics's common stock increased by 2.9% year-over-year, from $138K to $142K.
- What is the long-term trend for Corcept Therapeutics's common stock?
- Over 5 years (2020 to 2025), Corcept Therapeutics's common stock has grown at a 2.8% compound annual growth rate (CAGR), from $122K to $140K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Corcept Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude